Department of Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.
J Neurooncol. 2023 Nov;165(2):271-278. doi: 10.1007/s11060-023-04478-1. Epub 2023 Nov 10.
Microneurosurgical techniques have greatly improved over the past years due to the introduction of new technology and surgical concepts. To reevaluate the role of micro-neurosurgery in brain metastases (BM) resection in the era of new systemic and local treatment options, its safety profile needs to be reassessed. The aim of this study was to analyze the rate of adverse events (AEs) according to a systematic, comprehensive and reliably reproducible grading system after microneurosurgical BM resection in a large and modern microneurosurgical series with special emphasis on anatomical location.
Prospectively collected cases of BM resection between 2013 and 2022 were retrospectively analyzed. Number of AEs, defined as any deviations from the expected postoperative course according to Clavien-Dindo-Grade (CDG) were evaluated. Patient, surgical, and lesion characteristics, including exact anatomic tumor locations, were analyzed using uni- and multivariate logistic regression and survival analysis to identify predictive factors for AEs.
We identified 664 eligible patients with lung cancer being the most common primary tumor (44%), followed by melanoma (25%) and breast cancer (11%). 29 patients (4%) underwent biopsy only whereas BM were resected in 637 (96%) of cases. The overall rate of AEs was 8% at discharge. However, severe AEs (≥ CDG 3a; requiring surgical intervention under local/general anesthesia or ICU treatment) occurred in only 1.9% (n = 12) of cases with a perioperative mortality of 0.6% (n = 4). Infratentorial tumor location (OR 5.46, 95% 2.31-13.8, p = .001), reoperation (OR 2.31, 95% 1.07-4.81, p = .033) and central region tumor location (OR 3.03, 95% 1.03-8.60) showed to be significant predictors in a multivariate analysis for major AEs (CDG ≥ 2 or new neurological deficits). Neither deep supratentorial nor central region tumors were associated with more major AEs compared to convexity lesions.
Modern microneurosurgical resection can be considered an excellent option in the management of BM in terms of safety, as the overall rate of major AEs are very rare even in eloquent and deep-seated lesions.
由于新技术和手术理念的引入,过去几年微神经外科技术有了很大的进步。为了重新评估在新的全身和局部治疗方案时代微神经外科在脑转移瘤(BM)切除中的作用,需要重新评估其安全性。本研究的目的是分析在一个大型现代微神经外科系列中,根据一种系统、全面且可靠可重复的分级系统,对接受微神经外科 BM 切除术后的不良事件(AE)发生率,特别强调解剖部位。
回顾性分析了 2013 年至 2022 年期间 BM 切除术的前瞻性收集病例。根据 Clavien-Dindo-Grade(CDG)评估 AE 的数量,定义为任何与预期术后过程的偏差。使用单变量和多变量逻辑回归以及生存分析评估患者、手术和病变特征,包括确切的肿瘤解剖位置,以确定 AE 的预测因素。
我们确定了 664 名符合条件的肺癌患者,最常见的原发性肿瘤为肺癌(44%),其次是黑色素瘤(25%)和乳腺癌(11%)。29 名患者(4%)仅接受活检,而 637 名患者(96%)接受了 BM 切除术。出院时的总体 AE 发生率为 8%。然而,严重的 AE(≥CDG 3a;需要在局部/全身麻醉下进行手术干预或 ICU 治疗)仅发生在 12 例(1.9%)病例中,围手术期死亡率为 0.6%(4 例)。颅后窝肿瘤位置(OR 5.46,95%CI 2.31-13.8,p=0.001)、再次手术(OR 2.31,95%CI 1.07-4.81,p=0.033)和中央区域肿瘤位置(OR 3.03,95%CI 1.03-8.60)在多变量分析中显示为主要 AE(CDG≥2 或新的神经功能缺损)的显著预测因素。与凸面病变相比,深部幕上和中央区域肿瘤均与更多的主要 AE 无关。
在安全性方面,现代微神经外科切除术可被视为治疗 BM 的一种极好选择,因为即使在重要区域和深部病变中,严重 AE 的总体发生率也非常罕见。